Polycystic ovary syndrome (PCOS) is one of the most common endocrine-metabolic disorders; however, its pathophysiology is still unclear. Certain polymorphisms of luteinizing hormone betasubunit (LHb) and LH/choriogonadotrophin receptor (LHCGR) genes may lead to changes in the bioactivity of this hormone. We aimed to investigate possible associations between polymorphisms in the LHb and LHCGR genes and PCOS among Egyptian women. We also aimed to shed light on the impact of these polymorphisms on LH level, hormonal, and metabolic features of PCOS. A case-control study included unrelated 210 patients with PCOS and 200 healthy controls, and they were stratified according to their body mass index into two subgroups: lean and obese. Polymorphisms of LHb G1502A and LHCGR [G935A, and ins18LQ] genes were genotyped using polymerase chain reaction-restriction fragment length polymorphism. Our results revealed that LHb G1052A GA genotype and A allele, LHCGR G935A GA, AA genotypes, or A allele were significantly associated with PCOS risk, while the LHCGR ins18LQ polymorphism was not. Additionally, there is a synergism between LHb G1052A minor A and minor A allele of LHCGR G935A or minor ins allele of LHCGR ins18LQ and susceptibility to PCOS. When we stratified PCOS women or controls into obese and lean subjects, we found that LHb G1502A GA genotype and A allele being more frequent in the obese group when compared with lean patients with PCOS [The odds ratio and 95% confidence interval were 5.6 (1.30-24.56) and 5.15 (1.21-21.90), respectively, P 5 0.01, for each group.] These results suggested that LHb G1052A and LHCGR G935A genes polymorphisms are associated with increased risk of PCOS in Egyptian women especially in obese cases. There was a synergism between LHb G1052A minor A allele and of LHCGR G935A minor A or minor ins alleles of LHCGR ins18LQ and PCOS risk. V C 2015 IUBMB Life, 68(1): [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] 2016 
Introduction
Polycystic ovary syndrome (PCOS) is the most common ovarian disorder that affects 6-10% of reproductive-age women worldwide (1) and accounts for 70% of cases of anovulatory infertility (2) . Clinical manifestations of PCOS include menstrual irregularity, hirsutism, acne, infertility, and/or alopecia (3) . Its endocrinal features include hyperandrogenism, high levels of luteinizing hormone (LH) with normal levels of folliclestimulating hormone (FSH), and higher values of the LH/FSH ratio. PCOS also has significant psychological features, including increased anxiety, depression, and worsened quality of life (3) . In addition, women with PCOS suffer from metabolic abnormalities including insulin resistance (IR), compensatory hyperinsulinemia, central obesity (4) , and type 2 diabetes mellitus (5) . PCOS is a complex disorder, in which both environmental and genetic factors contribute to its pathogenesis (6) . Despite extensive research, the precise pathophysiology of PCOS remains largely obscure. New theories have been introduced, and considerable interest in the genetics of PCOS has increased considerably during the recent years (7) .
LH is a member of the glycoprotein hormone family that also includes FSH, thyroid-stimulating hormone, and human chorionic gonadotropin (hCG). These hormones are a:b heterodimers, in which the a-subunit is common to all hormones and the b-subunit is unique and confers biologic specificity (8, 9) . The two LH subunits (a and b) are encoded by separate genes, the former in chromosome 6 and the latter in chromosome 19 (10) . LH stimulates follicular development, steroidogenesis, and the formation of corpus luteum (11) , and ovulation results from a surge in LH levels (12) . LH acts by binding its highaffinity receptor, LH/choriogonadotrophin receptor (LHCGR), which also serves as the receptor hCG (11) . The effect of LH is mediated by LHCGR, which is expressed in the theca cells and granulose cells. Abnormal LH signaling is believed to play a permissive role in augmenting ovarian androgen production in PCOS and leading to anovulation (13, 14) .
Reports have shown that LH beta-subunit gene (LHb) and LHCGR genes polymorphisms may change the structure or function of the LH and LHCGR, either activating or inactivating their bioactivity, which cause anovulation, amenorrhea, and PCOS in women (15, 16) . There are compelling evidences for the genetic associations of LHb and LHCGR polymorphisms with PCOS, although the results of different populations and loci of polymorphisms showed inconsistencies (17) . A report by Ramanujam et al. (18) found that LHb G1052A polymorphism, in exon 3 (Gly102Ser), was higher in Singapore Chinese women who had menstrual disorders.
The LHCGR gene maps to chromosome 2p16.3, and several polymorphisms throughout the LHCGR gene were identified (9) . Notably, in this study, we selected LHGCR as the second gene of interest because of several factors as follows: it is found in the ovary on the theca cells and also present in the testis on the Leydig cells (19) , and it makes the receptor controlling the action of both LH and choriogonadotropin in the steroid biogenesis (20) . LHCGR encrypts a transmembrane integral protein, belonging to the G-protein-coupled receptor superfamily. It is composed of 11 exons occupying about 70 kbp. More than 300 single-nucleotide polymorphisms (SNPs) have been identified in the LHCGR gene (http://SNPper.chip. org), with an average spacing of 306 bp, and they are mostly situated in intronic sequences. We have selected, among the most frequent SNPs located in the coding region, those which may modulate the receptor activity of the LHCGR gene product. In particular, G935A variant, located in exon 10, is the most common SNP which manipulates the LHCGR gene products (21). Bhowmick et al. (22) suggested that G935A variant is involved in the transduction of LH but not of hCG signal and are next to the glycosylation signals of the protein and may thus affect translocation and stability of the receptor. Moreover, ins18LQ, caused by the insertion of a hexanucleotide in position 54 of the mRNA, is located in the signal peptide of the receptor and has been associated with an increase in both expression and bioactivity of the LHCGR (21). However, to the best of our knowledge, no data are available on the functional effect of these variants on receptor activity.
PCOS is a multifactorial disease with various genetic etiologies and few reports concerning its susceptibility with LHb and LHCGR polymorphisms; however, these results were conflicting in different populations. To the best of our knowledge, there was only one report, in relatively small sample size, by Bassiouny et al. (23) which demonstrated that LHCGR G935A polymorphism was associated with PCOS in Egyptian women. Therefore, the aim of our study was to investigate the possible associations of LHb G1502A and LHCGR [G935A, and ins18LQ] genes polymorphisms with susceptibility to PCOS. We also aimed to clarify the impact of these polymorphisms on LH level, hormonal, and metabolic features of PCOS.
Materials and Methods
This case-control study included 410 unrelated women: 210 patients with PCOS and 200 healthy women with regular menses and ultrasonographically normal ovaries, and they were matched to cases by age, body mass index (BMI), and ethnic origin (Egyptian). The clinical, biochemical, and hormonal profiles of controls were within normal limits, and they were studied in the follicular phase of their menstrual cycle. All patients were recruited from outpatient clinics of the Endocrinology Unit of Internal Medicine and Obstetrics and Gynecology Departments, Faculty of Medicine, Zagazig University, Egypt, and the Obstetrics and Gynecology Department, Faculty of Medicine, Benha University, Egypt. The diagnosis of PCOS was based on the 2004 revised Rotterdam criteria (24) . At least two of the following three features needed to be present: 1) oligo-ovulation or anovulation (<6 menstrual periods per year); 2) clinical and/or biochemical signs of hyperandrogenism, including hirsutism (Ferriman-Gallwey score > 8), and/or total testosterone level >0.8 ng/mL); and 3) sonographic evidence of PCOS. Other causes of oligomenorrhea were excluded in patients with PCOS.
All women underwent complete history, including cycle length and thorough clinical examination. Body weight had to be stable for at least 3 months before the study. All subjects were on an unrestricted diet and were instructed not to modify their usual eating patterns. We assessed clinical and anthropometrical variables, including blood pressure, BMI, and waist/ hip ratio (WHR) in all participants. Exclusion criteria for all women included a history of hyperandrogenic states (such as nonclassic congenital adrenal hyperplasia, androgen secreting tumors, Cushing's syndrome, 21-hydroxylase deficiency, or hyperprolactinemia), diabetes mellitus, hypertension, liver, kidney, or thyroid diseases. In addition, all participants did not take any medication known to affect endocrine parameters, metabolism, or inflammation and recent/current at the start of this study and during the preceding 3 months illness. Cases and controls were then stratified according to the degree of obesity into two groups [lean, BMI < 25 kg/m 2 ; and obese,
.
Ethical Consideration
A written informed consent was taken from all of the participants after explaining details and benefits as well as risks to them. The ethical committee of Faculties of Medicine, Zagazig and Benha Universities approved our study protocol and the written informed consent assigned by all participants.
Biochemical Measurements
Blood samples were drawn from all subjects during the early follicular phase of the menstrual cycles after an overnight fast.
We divided blood sample into three portions: 1 mL of whole blood was collected into tubes containing EDTA for determination of HbA1c and DNA extraction. Second, 1 mL of whole blood was collected into tubes containing fluoride for fasting blood glucose estimation. Sera were separated immediately from the remaining third portion and stored at 2208C until analyses of other parameters. Fasting blood glucose was determined using the glucose oxidase method (Spinreact, Girona, Spain). Total cholesterol, HDL cholesterol, and triglycerides levels were measured by routine enzymatic methods (Spinreact). The LDL cholesterol level was calculated using the Friedewald formula (26).
Immunochemical Measurements
We estimated FSH, LH, and prolactin concentrations using chemiluminescence immunoassay kit provided by Immunospec Corporation (Canoga Park, CA, USA 
DNA Extraction
Genomic DNA was extracted from EDTA whole blood using a spin-column method according to the protocol (QIAamp Blood Kit; Qiagen, GmbH, Hilden, Germany). DNA was stored at 2208C till the time of use.
Genotyping of LHb and LHCGR Genes Polymorphisms
Genotyping for the LHb G1502A (rs1056917), in exon 3, and LHCGR [G935A (rs2293275) in exon 10 and ins18LQ (rs4539842) in exon 1] genes polymorphisms was performed by a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method described by Lee et al. (30) and Capalbo et al. (31) , respectively. The PCR primers were designed on the basis of open access program Primer3 (http:// www. bioinfo.ut.ee/primer3-0.4.0), and they were also similar to primer sequences in a studies previously described (30, 31) . . The PCR protocols of LHb G1502A, LHCGR G935A, and LHCGR ins18LQ were performed with the following settings: 948C for 4 min, followed by 35 cycles at 948C for 30 sec, 658C for LHb G1502A, 548C for LHCGR G935A, 568C of LHCGR ins18LQ for 30 sec, and 728C for 45 sec. A final extension step was carried out at 728C for 7 min. All PCR products were digested with restriction enzymes (Fermentas, Germany) according to the manufacturer's instruction. The fragments were resolved by gel electrophoresis in a 2.5% agarose gel (Serva, Spain) stained with ethidium bromide and visualized under a UV transilluminator. A 50-bp ladder (Fermentas) was used as a marker. PCR primer sequences, restriction enzymes, and fragments sizes are listed in Table 1 . Notably, 10% of the samples were amplified twice for checking the accuracy of the results. Retested samples were randomly chosen, and retesting was performed to control the test process.
Statistical Analysis
Statistical analyses were performed using the Statistical Package for the Social Sciences for Windows (version 17.0; SPSS, Chicago, IL, USA). Data were expressed using descriptive statistic (mean 6 standard deviation) and were analyzed using ttest. One-way analysis of variance (ANOVA) test was done to compare different parameters between more than two groups. Genotype frequencies in cases and controls were tested for Hardy-Weinberg equilibrium, and any deviation between the observed and expected frequencies was tested for significance using the chi-square (v 2 ) test. The statistical significances of differences in the frequencies of variants between the groups were tested using the v 2 test. In addition, the odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated as a measure of the association of LHb G1502A and LHCGR [G935A and ins18LQ] genotypes with PCOS. The appropriate sample size and power of the study were determined using PAWE-3D (32). PAWE-3D calculations showed that the sample size, together with the specified study design, allele frequencies, prevalence of disease, and allowable error rates, can give as high as 90% power and can detect the variant allele frequency of at least 0.05 and genotype relative risk of more or equal to 1.8 at 80% power. ANOVA test or unpaired Student's t-test (T test) was done to compare different clinical, biochemical, and hormonal parameters of the PCOS parameters among three genotypes variants. A difference was considered significant at P < 0.05.
Results

Clinical and Laboratory Characteristics of the Study Subjects
Clinical and laboratory characteristics of the study subjects are presented in Table 2 . Patients with PCOS had significantly higher values of WHR, hirsutism score, triglycerides, fasting insulin, HOMA-IR, and HOMA-b when compared with controls. Additionally, patients with PCOS had higher total and free testosterone, LH, LH/FSH, dehydroepiandrosterone sulfate (DHEA-S), FAI, prolactin levels, ovarian volume, and antral follicle count (AFC) values more than healthy women. On the contrary, patients with PCOS had significantly lower levels of QUICKI, SHBG, FSH, and androstenedione when compared with controls. Our patients with PCOS had higher frequencies of LHCGR G935A GA genotype (GA 5 44.8% vs. 27%), whereas the AA genotype was not detected in control group. The MAF, A allele, was 13.5% in healthy women and 41.9% of PCOS cases. After comparing cases and healthy women, it was evident that the presence of the GA genotype or A allele was strongly associated with PCOS [OR (95% CI) 5 3.4 (2.19-5.24), P < 0.001 and OR (95% CI) 5 1.5 (1.35-1.77), P < 0.001, respectively).
Distribution of Genotype and Allele Frequencies of
On the contrary, no significant differences were demonstrated in the distribution of LHCGR ins18LQ genotypes and alleles between patients with PCOS and controls.
Synergistic Effect of LHb and LHCGR Polymorphisms and Developing PCOS
We investigated if there is any synergistic effect between minor alleles of LHb and LHCGR SNPs which may subsequently affect PCOS risk. The risk of PCOS was significantly higher among patients carrying minor A allele of LHb G1052A 1 LHCGR G935A minor A allele than those noncarriers [OR (95% CI) 5 2.8 (1.98-4.00), P < 0.001 synergistic index (SI) 5 2.9; Table 4 ]. Surprisingly, after comparing cases and healthy women, it was evident that the presence of both LHb G1052A minor A allele 1 LHCGR ins18LQ ins minor allele was significantly associated with 
Genotype and Allele Frequencies of LHb and LHCGR
Genotypes and Their Allele Frequencies in PCOS Cases and Controls When Stratified by BMI
As obesity is a common feature of PCOS and plays an important role in its pathogenesis, we stratified controls and patients with PCOS into lean and obese subgroups ( Table 6 ). As the majority of our patients with PCOS were obese (77.1%), we matched the healthy women to cases. In PCOS patients, the GA genotype and A allele of LHb G1502A were more frequent in the obese subgroup when compared with lean subgroup (15.3% vs. 0.9% and 7.6% vs. 0.5%, respectively). The OR and 95% CI were 5.6 (1.30-24.56) and 5.15 (1.21-21.90), respectively, P 5 0.01, for each group. However, no significant differences were detected in the distribution of genotypes or alleles between lean and obese subgroups within controls. These findings suggested that there were obesity-PCOS-LHb G1052A genotype interactions. Among our controls, the GA genotype of LHCGR G935A was more frequent in the obese subgroup when compared with lean subgroup [20% vs. 7%, the OR and 95% CI was 19.05 (6.65-54.54), P < 0.001], whereas there was no significant difference between lean and obese subgroups among PCOS cases regarding the LHCGR G935A genotypes and allele frequencies. Moreover, our findings did not reveal any significant differences in distributions of LHCGR ins18LQ genotypes or alleles between lean and obese subgroups among PCOS cases or controls.
Interestingly among our obese patients, the LHb G1052A GA genotype and A allele were more frequent in PCOS patients more than controls. The OR and 95% CI were 6.9 (2.62-18.35) and 19.96 (7.56-52.74), respectively, P < 0.001, for each group. While within lean subjects, we didn't find any significant difference between PCOS cases and controls. These data demonstrated that there were obesity-LHb G1502A genotype interactions.
Notably within obese cases, LHCGR G935A GA, AA genotypes and A allele were more frequent in PCOS patients than in controls. The OR (95% CI) 3.5 (2.18-5.94); 1.5 (1.32-1.79); 4.6 (3.06-6.80), respectively, P < 0.001 for each group. Similarly within lean subjects, LHCGR G935A GA, AA genotypes and A allele were more frequent in PCOS patients than in controls. The OR (95%CI) :2.7 (1.11-6.57), P 5 0.03; 1.6 (1.2-
Distribution of LHb and LHCGR genotypes and allele frequencies in healthy controls and patients with PCOS
Controls
Patients with PCOS n 5 200 n 5 210 n (%) n (%) P 
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Impact of LHb and LHCGR Genes Polymorphisms on Clinical, Biochemical, and Hormonal Characteristics Among Patients with PCOS
Among patients with PCOS, we found that LHb G1502A polymorphism was significantly associated with increased fasting blood glucose, HbA1c, HOMA-IR, QUICKI, and total and free testosterone levels (Table 7) . However, carriers of the LHb G1052A A allele showed lower LH levels when compared with noncarriers (11.4 6 3.1 vs. 13.1 6 3, P 5 0.003; Fig. 1 ). We further analyzed these results using univariate and multivariate analyses after adjustment for the effect of LH level to confirm the effect of LHb G1052A variants on the phenotypes of PCOS. Our results demonstrated that there was a significant increase of fasting blood glucose, HbA1c (%), HOMA-IR, QUICKI, and total and free testosterone levels (P < 0.001 for all, except for total and free testosterone P 5 0.02, P 5 0.01 respectively) in mutant GA variants when compared with wild GG. Also, we found significant increase of total cholesterol and triglycerides levels among patients with PCOS with LHb GA genotype when compared with wild (GG) carriers (P 5 0.03, P 5 0.01, respectively). This supports the hypothesis that SNP may increase the bioactivity of LH.
Moreover, we found significant associations of LHCGR G935A polymorphism with elevated values of diastolic blood pressure, hirsutism scores, total cholesterol, fasting blood glucose, HbA1c, HOMA-b, LH/FSH, FAI, prolactin, AFC, and ovarian volume, whereas HDL cholesterol levels were significantly decreased among PCOS cases. Interestingly, we observed significant associations of LHCGR ins18LQ with increased levels of WHR, fasting blood glucose, HbA1c, FAI, prolactin, AFC, and ovarian volume; however, HDL cholesterol and SHBG levels were significantly decreased among patients with PCOS ( Table 7) . The LH levels were significantly increased in mutant homozygous and heterozygous variants of LHCGR G935A and ins18LQ when compared with wild variants (Figs. (2) and (3) respectively). (20) 106 (53) 19 (9) 56 (26.7) GA 14 (7) 40 ( 
Discussion
PCOS is one of the most common endocrine-metabolic disorders (17) . Recently, many studies suggested that genetic factors were strongly associated with the etiology of PCOS (6, 7, 17, 23) . However, only a few genes were found to have association with PCOS or some clinical traits related to PCOS (17) . Until now, the relationship between LH signaling pathway and PCOS has not been defined clearly (7) . Few previous studies concerning the role of LHb and LHCGR polymorphisms in PCOS have provided conflicting results. To our knowledge, there was only one report by Bassiouny et al. (23) , in our population on relatively small sample size, investigating the association of LHCGR G935A SNP with PCOS in Egyptian women. Therefore, in this integrated study we investigated, for the first time, the possible associations of three genes polymorphisms [LHb G1502A and LHCGR (G935A, and ins18LQ)] with susceptibility to PCOS, and we also tried to clarify the influence of these polymorphisms on LH level, hormonal, and metabolic features of PCOS. In this study, we found significantly higher levels of triglycerides in patients with PCOS when compared with controls. These results confirmed the results of previous studies by Wijeyaratne et al. (33) and Wild et al. (34) . On the contrary, Phelan et al. (35) and Fulghesu et al. (36) found no significant difference in triglycerides between healthy women and PCOS cases.
In our study, the frequency of LHb G1052A heterozygous variant was significantly increased in patients with PCOS when compared with controls (16.2% vs. 3.5%; P < 0.001). Interestingly, the AA genotype was not detected in both groups. In our Egyptian control sample, the MAF, A allele, was 1.7%. Similar to our finding, Hashad et al. could detect A allele in Egyptian healthy males. Moreover, they suggested that this SNP can be population-specific and is relatively common in the Egyptian population (37) . On the contrary, reports by Liu et al. (7) in the Chinese Han population and by Ramanujam et al. (18) in the Singapore Chinese population revealed absence of A allele in their control subjects. LH levels in LHb G1502A genotypes among patients with PCOS. Our findings revealed that the frequency of A allele in PCOS cases was significantly higher than healthy women (P < 0.001). These data were in agreement with the previous reports (7, 18) . Ramanujam et al. (18) speculated that LHb G1052A polymorphisms affected gonadal function and that the microheterogeneity was related to menstrual irregularity (14) . Notably, Kim et al. (38) found that none of the Korean patients with PCOS were LHb G1052A homozygous gene variants (15) . On the other hand, Ramanujam et al. (39) did not find any variant either in Malay or Indian women with PCOS. These results suggested that ethnicity and environment may influence the genetic variability in patients with PCOS.
In this study, the MAF of LHCGR G935A was 13.5% in healthy women and 41.9% of PCOS cases. We found significant associations of PCOS with GA genotype or A allele [OR (95% CI) 5 3.4 (2.19-5.24), P < 0.001 and OR (95% CI) 5 1.5 (1.35-1.77), P < 0.001, respectively]. Furthermore, AA genotype was not detected in the control group. In line with our data, the AA genotype was absent in Bahraini Arab, Egyptian, and Caucasian healthy women (6, 23, 40) . Ha et al. (17), Bassiouny et al. (23) , and Capalbo et al. (31) have found that the G935A polymorphism of LHCGR gene is associated with PCOS in Hui Chinese, Egyptian, and Sardinian populations, which was similar to our findings. On the contrary, Almawi et al. (6) and Valkenburg et al. (41) reported that G935A polymorphism was not obviously associated with PCOS in Bahraini Arab and Caucasian populations. On the contrary, Thathapudi et al. (42) revealed that the GG genotype, rather than AA, conferred a significant risk of developing PCOS in South Indian women. These conflicting findings among the studies could be explained by differences in sample size, ethnic background, selection of cases and controls, and study design.
Our results showed that the frequencies of genotypes and alleles of LHCGR ins18LQ were not statistically significant between the PCOS and control groups. Similar to our data, Liu et al. (7) did not demonstrate any significant association between PCOS and LHCGR ins18LQ SNP in Chinese Han women. In contrast, Valkenburg et al. (41) found that LHCGR 18insLQ insertion allele frequency was significantly lower in Caucasian patients with PCOS than controls.
This study demonstrated for the first time that the risk provided by minor A allele of LHb G1052A was found to be positively reinforced by A minor A allele of LHCGR G935A (SI 5 2.9). Moreover, the novel finding in this study was the presence of a synergism between minor A allele of LHb G1052A gene and ins allele of LHCGR ins18LQ gene and the risk of developing PCOS in Egyptian females (SI 5 1.43). To the best of our knowledge, this is the first study to report such an association.
Till date, the relationship between LH signaling pathway and PCOS has not been clearly defined. Besides the two-celltwo-gonadotrophin theory, LH plays a critical role in the folliculogenesis. During the second half of the follicular phase, LH regulates mRNA concentrations in granulose cells for numerous genes that function in autocrine and paracrine signaling, which can help the follicle development (43, 44) . LH promotes the secretion of androgens by ovarian theca cells, which may result in follicular maturation arrest (40) . LHCGR is overexpressed in theca cells and granulose cells from patients with PCOS (45, 46) . Thus, these functional SNPs have been described in LH and LHCGR genes, which may affect the LH and LHCGR bioactivities (21, 47) .
In the current study, the majority of our PCOS patients were obese (77.1%). These results were in agreement with previous reports (48) (49) (50) . Moreover, Pasquali et al. (51) suggested that the reproductive phenotype of PCOS can be reversed by weight loss in obese women.
Indeed, obesity is a common feature of PCOS that worsens its phenotype, and therefore, we have also analyzed whether the LHb and LHCGR polymorphisms were associated with LH levels in LHCGR G935A genotypes among patients with PCOS.
LH levels in LHCGR ins18LQ genotypes among patients with PCOS . However, we did not find any significant differences between lean and obese PCOS cases regarding the LHCGR [G935A and ins18LQ] genotypes and alleles frequencies. This could be explained as hyperandrogenemia and is considered as one of the most important pathophysiological features in PCOS (52) , and obesity aggravates menstrual irregularity and increases serum total testosterone level (53) . Thus, this androgen excess can affect the follicle growth and metabolic process, playing a key role in the occurrence and the development of PCOS in the obese women (6, 54) .
Among our PCOS patients, the carriers of the LHb 1052A allele had higher fasting blood glucose level (88.9 6 2.1 vs. 86.7 6 2 mg/dL, P 5 0.001). Our results were consistent with that of Liu et al. (7) who found that the LHb 1052A allele had higher fasting glucose level. Higher fasting glucose usually represents IR or metabolic dysfunction, which is one of the most common clinical features of PCOS. Studies have confirmed that insulin can enhance the responsiveness of theca cell and granulose cell to LH in PCOS women (46) . IR and LH interacted with each other and affect the phenotype of PCOS.
Interestingly, carriers of the LHb 1052A allele showed lower LH level (P 5 0.003) and higher total and free testosterone levels (P 5 0.03 and P 5 0.01, respectively). These results were in agreement with Liu et al. (7) who demonstrated that LHb 1052A allele carrier had lower LH levels when compared with the wild-type G allele carrier. Researchers have shown that LHb and LHCGR polymorphisms may change the structure or function of the LHb and LHCGR, either activating or inactivating their bioactivity, which cause PCOS (15, 16) . Haavisto et al. (55) reported that LHb G1502A alters the biological function of LH with an elevation of in vitro bioactivity when compared with that of the wild-type LHb. Our results, using univariate and multivariate analyses after adjusting the effect of LH level, demonstrated that there was a significant increase of fasting blood glucose, HbA1c (%), HOMA-IR, QUICKI, total and free testosterone, total cholesterol, and triglycerides levels among LHb G1052A GA carriers when compared with wild type (GG) in patients with PCOS. This supports the hypothesis that SNP may increase the bioactivity of LH. Notably, LH plays an important role in secreting testosterone. This phenomenon strongly suggested that LHb G1052A gene variants had an effect on LH protein and may enhance the LH bioactivity. Little is known about how this rare variant affects the functionality of LH. With a possible explanation on the basis of in vivo experiments, Wide et al. showed that an extra glycosylation site on the mutant variant LHb when compared with the wild type allows for greater sialylation and results in a longer halflife in serum. Granulosa cells are triggered typically by distinct pulses of LH; however, because of its prolonged residence in serum, granulosa cells are exposed to decreased pulse amplitudes of variant LH. Thus, Wide et al. (56) proposed that the longer half-life of A allele variant LHb may be a contributing factor to the reproductive disorders observed. In contrast, Lamminen et al. (57) had found that the LHb G1052A SNP may not affect receptor binding and bioactivity of LH. Interestingly, PCOS is a heterogeneous endocrine disorder, which is involved in many factors such as genetics and environment factors. So, the biological function of LHb 1052A gene variants within PCOS microenvironment needs to be further studied.
In the current study, we found significant increase of LH levels among LHCGR [G935A and ins18LQ] mutant homozygous and heterozygous variants when compared with wild variants among patients with PCOS, which agree with the results given by Piersma et al. (21) . The same authors also suggested that LHCGR G935A and 18insLQ polymorphisms render the LHR bioactivity, indicating LHR was insensitive to increased LH levels (21) . In addition, Segaloff revealed that mutant homozygous or heterozygous inactivating gene variants of the LHCGR cause gonadal resistance to LH, and the latter event causes feedback to pituitary to result in the rising LH level. However, the clinical phenotypes are closely correlated with the severity of the SNPs (58) .
Additionally, there were significant increases of LH/FSH and FAI values among LHCGR G935A A allele and LHCGR ins18LQ insertion allele carriers when compared with G and noninsertion alleles carriers (LH/FSH: P 5 0.006, P 5 0.03 and FAI: P 5 0.001, P < 0.001, respectively). High LH level is a significant character of PCOS. Although LH level was no longer as a diagnostic factor of PCOS in the 2004 revised Rotterdam criteria, LH level or LH/FSH ratio still acts as a diagnostic criterion of PCOS in some Asian countries such as Japan (59) . Notably, Al Kindi et al. (29) concluded that diagnosis of hyperandrogenism was most accurate when using FAI rather than testosterone alone.
This study was well designed and focused on the influence of LHb and LHCGR genes variants on LH levels on metabolic and biochemical phenotypes of PCOS. Consequently, future multicenter studies including larger sample size and analyzing more SNPs are necessary to clarify the role of these polymorphisms in PCOS and its effects on disease phenotypes among Egyptian patients.
In conclusion, we found for the first time that genotype frequencies of LHb G1052A G/A, A allele, LHCGR G935A G/A, and AA genotypes A allele were significantly higher in Egyptian patients with PCOS when compared with the control group; however, no significant differences were observed in LHCGR ins18LQ genotypes and alleles distributions. In addition, there is a synergism between minor A allele of LHb G1052A and minor A allele of LHCGR G935A or minor ins allele of LHCGR ins18LQ regarding the risk of development of PCOS. This is the first study to show that LHb G1502A GA genotype and A allele were more frequent in the obese PCOS women when compared with lean patients. We demonstrated a significant increase of LH levels among LHCGR G935A A allele and LHCGR ins18LQ insertion allele carriers when compared with those carrying G and noninsertion alleles; however, the carriers of the LHb 1052A allele showed lower LH level.
